

EN
E-004816/2025
Answer given by Mr Várhelyi
on behalf of the European Commission
(30.1.2026)

On 8 February 2018, the medicinal product Ozempic (active substance semaglutide) was granted a marketing authorisation valid across the European Union¹. Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise².

Related medicinal products, namely Saxenda (liraglutide)³, Wegovy (semaglutide)⁴ and Mounjaro (tirzepatide)⁵ were granted EU marketing authorisations on 23 March 2015⁶, 6 January 2022⁷ and 15 September 2022⁸, respectively. They are indicated to help manage weight along with diet and increased physical activity.

The active substances semaglutide, liraglutide and tirzepatide are all glucagon-like peptide-1 (GLP-1) receptor antagonists. Tirzepatide has an additional mechanism of action as it also targets GIP (glucose-dependent insulinotropic polypeptide) receptors.

As indicated in the publicly available product information for Ozempic (page 29)⁹, Saxenda (page 25)¹⁰, Wegovy (pag 33)¹¹ and Mounjaro (pag 40)¹², all these medicinal products are subject to medical prescription.

The Commission has no competence to reply on the question whether Ozempic or Ozempic-similar medicines will become more affordable and under which conditions, as decisions on pricing and reimbursement of medicines are a competence and responsibility of the Member States according to Article 168(7) of the Treaty on the Functioning of the European Union.

¹ <https://ec.europa.eu/health/documents/community-register/html/h1251.htm>.

² <https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic>.

³ <https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda>.

⁴ <https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy>.

⁵ <https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro>.

⁶ <https://ec.europa.eu/health/documents/community-register/html/h992.htm>.

⁷ <https://ec.europa.eu/health/documents/community-register/html/h1608.htm>.

⁸ <https://ec.europa.eu/health/documents/community-register/html/h1685.htm>.

⁹ https://ec.europa.eu/health/documents/community-register/2025/20250917167540/anx_167540_en.pdf.

¹⁰ https://ec.europa.eu/health/documents/community-register/2025/20250625166765/anx_166765_en.pdf.

¹¹ https://ec.europa.eu/health/documents/community-register/2025/20250730166852/anx_166852_en.pdf.

¹² https://ec.europa.eu/health/documents/community-register/2025/20250214164978/anx_164978_en.pdf.